The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2007, 179, 2961 -2968
Copyright © 2007 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jin, N.
Right arrow Articles by Born, W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jin, N.
Right arrow Articles by Born, W. K.
Right arrowPubmed/NCBI databases
*Substance via MeSH

Airway Hyperresponsiveness through Synergy of {gamma}{delta} T Cells and NKT Cells1

Niyun Jin*,{dagger}, Nobuaki Miyahara{ddagger}, Christina L. Roark*,{dagger}, Jena D. French*,{dagger}, M. Kemal Aydintug*,{dagger}, Jennifer L. Matsuda*,{dagger}, Laurent Gapin*,{dagger}, Rebecca L. O’Brien*,{dagger}, Erwin W. Gelfand{ddagger} and Willi K. Born2,*,{dagger}

* Integrated Department of Immunology, National Jewish Medical and Research Center, Denver, CO 80206; {dagger} University of Colorado at Denver Health Sciences Center, Denver, CO 80206; and {ddagger} Division of Cell Biology, Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO 80206


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Mice sensitized and challenged with OVA were used to investigate the role of innate T cells in the development of allergic airway hyperresponsiveness (AHR). AHR, but not eosinophilic airway inflammation, was induced in T cell-deficient mice by small numbers of cotransferred {gamma}{delta} T cells and invariant NKT cells, whereas either cell type alone was not effective. Only V{gamma}1+V{delta}5+ {gamma}{delta} T cells enhanced AHR. Surprisingly, OVA-specific {alpha}β T cells were not required, revealing a pathway of AHR development mediated entirely by innate T cells. The data suggest that lymphocytic synergism, which is key to the Ag-specific adaptive immune response, is also intrinsic to T cell-dependent innate responses.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Adaptive immunity depends on the synergistic actions of different lymphocyte types. The best-studied example is the development of humoral responses to T-dependent Ag, which requires synergism of Ag-specific T and B cells (1). Likewise, the development of Ag-specific CTL is aided by Ag-specific Th cells (2). In addition, the development of the Ag-specific immune responses appears to benefit from the synergistic action of innate T cells (3), but it is not known whether innate T cells also synergize with one another during innate immune responses.

In the pathogenesis of allergic airway diseases, Ag-specific memory T cells and allergen-specific Abs are considered key (4). Studies in humans and rodents indicate important roles for classical CD4+ and CD8+ {alpha}β T cells in allergic inflammation (5, 6), but nonclassical T cells including NKT cells (7, 8) and {gamma}{delta} T cells (9, 10) have been implicated in allergic airway disease as well (11).

NKT cells are innate {alpha}β T cells with a restricted TCR repertoire, which coexpress receptors of the NK lineage (12), and participate in protective and pathological host responses (13, 14), and in allergic airway disease (15). In allergen-sensitized mice, allergen-nonspecific NKT cells expressing invariant TCRs (iNKT)3 increase airway inflammation and airway hyperresponsiveness (AHR), without a requirement for allergen priming (7, 8). iNKT cells express a semi-invariant TCR{alpha} chain (V{alpha}14-J{alpha}18) in association with Vβ8, Vβ7, and Vβ2, and recognize glycolipids presented by the MHC class I-like CD1d molecule (16). They can be detected by staining with tetramerized CD1d/β2-microglobulin (β2m) heterodimeric molecules complexed with the pharmacological ligand {alpha}-galactosylceramide ({alpha}GalCer) (17). iNKT cells in C57BL/6 mice also express the NK receptor NK1.1, which is acquired during the final stages of their development (18). Like iNKT cells, {gamma}{delta} T cells also play a role in the lung pathology of allergen-sensitized mice (9, 10), particularly in the development of AHR. In OVA-sensitized and challenged mice, {gamma}{delta} T cells expressing V{gamma}1 enhanced AHR (19), whereas cells expressing V{gamma}4 strongly suppressed AHR (20, 21). The AHR-regulatory {gamma}{delta} T cells had only minor effects on airway inflammation, however, and they do not appear to recognize OVA (22). Notably, young adult mice (6–12 wk) require {gamma}{delta} T cells for the development of AHR following sensitization and challenge with OVA (19), even though older mice (>6 mo) develop AHR in the absence of {gamma}{delta} T cells (10).

AHR in mice genetically deficient in {gamma}{delta} T cells (B6.TCR-{delta}–/–) can be restored following adoptive transfer of small numbers of purified V{gamma}1+ {gamma}{delta} T cells from OVA-sensitized and challenged donors (19). Others have proposed that {gamma}{delta} T cells depend in their functions on interactions with {alpha}β T cells (23). AHR-suppressive {gamma}{delta} T cells do not require {alpha}β T cells (10), but it remained possible that the AHR-enhancing {gamma}{delta} T cells depend on {alpha}β T cells for this function. Our studies suggest that V{gamma}1+ {gamma}{delta} T cells and iNKT {alpha}β T cells synergize in the development of AHR, and that they depend on each other in this function.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Animals

C57BL/6, B6.TCR-β–/–, B6.TCR-{delta}–/–, and B6.TCR-β–/–{delta}–/– mice were purchased from The Jackson Laboratory. All mice were maintained on OVA-free diet. The mice were 8–12 wk old at the time of the experiments. All mice were cared for at National Jewish Medical and Research Center, following guidelines for immune-deficient animals. All experiments were conducted under a protocol approved by the Institutional Animal Care and Use Committee.

Sensitization and airway challenge

Groups of mice were sensitized by i.p. injection of 20 µg of OVA (OVA grade V; Sigma-Aldrich) emulsified in 2.25 mg of aluminum hydroxide (AlumImuject; Pierce) in a total volume of 100 µl on days 0 and 14 (2ip). Mice were challenged via the airways with OVA (10 mg/ml in saline) for 20 min each on days 28, 29, and 30, by ultrasonic nebulization (particle size 1–5 mm; De Vilbiss) (3N). Lung resistance (RL) and dynamic compliance (Cdyn) were assessed 48 h after the last allergen challenge, and the mice were sacrificed to obtain tissues and cells for additional analysis.

Bronchoalveolar lavage (BAL)

Immediately following measurements of AHR, lungs were lavaged and BAL fluid was recovered. Total leukocyte numbers were measured (Coulter Counter; Coulter Electronics). Differential cell counts were performed by light microscopy of cytocentrifuged preparations (Cytospin2, Cytospin; Thermo Shandon), stained with Leukostat (Fisher Scientific). For each sample, at least 200 cells were counted and differentiated by standard hematological procedures. All BAL cell counts and statistical analysis of differences are provided in Table I.


View this table:
[in this window]
[in a new window]

  		Table I. Cell numbers (x1000) and percentages, in the BAL fluid of cell transfer recipients (mean ± SEM)

 
Administration of anti-NK1.1 Abs

Anti-NK1.1 mAb PK136 was purified from hybridoma culture supernatant using a protein G-Sepharose affinity column (Pharmacia). Depletion of NK1.1+ cells was achieved after injection of 200 µg of purified anti-NK1.1 mAb into the tail veins of mice, 3 days before the first OVA challenge and/or cell transfer. Depletion was monitored by immunocytofluorimetry (FACScan).

Cell purification and adoptive transfer of T cells

Donor spleens were homogenized, treated with Gey’s solution for RBC removal, and passed through nylon wool columns for T cell enrichment. Nonadherent (NAD) cells were used for further purification. {alpha}β T cells were purified from sensitized TCR-{delta}–/– mice. NAD cells were stained with FITC-conjugated anti-TCR-β mAb H57.597, with biotinylated anti NK1.1 mAb, followed by PE-streptavidin, or with PE-conjugated anti NK1.1 mAb, or with {alpha}GalCer-loaded CD1d/β2m tetramer conjugated to PE, as previously described in detail (17). Stained cells were sorted on a MoFlow cell sorter (DakoCytomation), and collected at a purity of >95%. V{gamma}1+ {gamma}{delta} T cells were purified from the spleen of C57BL/6 or B6.TCR-β–/– mice. NAD cells were stained with biotinylated anti-V{gamma}1 mAb (24), and positively selected using streptavidin-conjugated magnetic beads (Streptavidin Microbeads; Miltenyi Biotec), as previously described in detail (22). Repeated selection produced a cell population containing >90% viable V{gamma}1+ cells, as determined by two-color staining with anti-TCR-{delta} GL3 and anti-V{gamma}1 mAbs. The purified cells were washed and resuspended in balanced salt solution, and injected via the tail vein into OVA-sensitized mice (B6.TCR-{delta}–/– or B6.TCR-β–/–{delta}–/–), <1 h before the first airway challenge.

Note: Throughout this work, we use the nomenclature for murine V{gamma} genes introduced by Heilig and Tonegawa (25). We use the term "enhancing" cells to refer to purified V{gamma}1+ {gamma}{delta} T cells capable of enhancing AHR upon adoptive cell transfer into OVA-sensitized and challenged recipients, and the term "suppressive" cells to refer to purified V{gamma}4+ {gamma}{delta} T cells derived from OVA-sensitized and challenged mice, which are capable of suppressing AHR.

Determination of airway responsiveness

Airway responsiveness was assessed as a change in lung function after provocation with aerosolized methacholine (MCh) using a method previously described in detail (10). MCh aerosol was administered for 10 s (60 breaths/min, 0.5 ml of tidal volume) in increasing concentrations. Maximum values of RL and minimum values of Cdyn were recorded and expressed as percentage of change from baseline after saline aerosol.

Statistical analysis

Data are presented as means ± SEM. The unpaired t test was used for two-group comparisons, and two-way ANOVA for analysis of differences in three or more groups. Pairwise comparisons were performed using the post-Bonferroni test. Statistically significant levels were set at a p value of <0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Like NKT cells, {gamma}{delta} T cells are considered part of the innate immune response. To test whether {gamma}{delta} T cells can enhance AHR likewise without allergen priming, we transferred 104 purified V{gamma}1+ {gamma}{delta} T cells from the spleen of untreated C57BL/6 mice into OVA-sensitized {gamma}{delta} T cell-deficient recipients (B6.TCR-{delta}–/–), just before OVA challenge. Without the transferred cells, the B6.TCR-{delta}–/– mice showed only weak responses to inhaled MCh, based upon the changes seen in RL and Cdyn (Fig. 1, a and b). When reconstituted with V{gamma}1+ cells from either sensitized or nonsensitized donors, they developed AHR (Fig. 1, a and b), indicating that the development of the AHR-enhancing {gamma}{delta} T cells does not require allergen priming or help from allergen-primed {alpha}β T cells. Notably, in this and subsequent experiments, the AHR-enhancing {gamma}{delta} T cells had little or no effect on eosinophilic airway inflammation (Table I).


Figure 1
View larger version (32K):
[in this window]
[in a new window]

  		FIGURE 1. V{gamma}1+ {gamma}{delta} T cells from naive donors enhance AHR when {alpha}β T cells are present. AHR was monitored by measuring RL (a, c, and e) and Cdyn (b, d, and f). a and b, Reconstitution of {gamma}{delta} T cell-deficient mice with V{gamma}1+ cells restores AHR. OVA-sensitized B6.TCR-{delta}–/– mice received 1 x 104 splenic V{gamma}1+ {gamma}{delta} T cells from untreated (NT) or sensitized (2ip) C57BL/6 donors, before airway challenge. Untreated recipients (NT) and recipients that were sensitized and challenged, but did not receive cells (2ip3N), are also shown. Results for each group are presented as means ± SEM (n = 8). Significant differences between 2ip3N and 2ip3N + V{gamma}1 groups are indicated: **, p < 0.01; ***, p < 0.001. c and d, V{gamma}1+ cells from {alpha}β T cell-deficient mice are still capable of restoring AHR. OVA-sensitized B6.TCR-{delta}–/– mice received 1 x 104 splenic V{gamma}1+ {gamma}{delta} T cells from untreated (NT) or sensitized (2ip) B6.TCR-β–/– donors, before airway challenge. Recipients that were sensitized and challenged, but did not receive cells (2ip3N), are also shown. Results for each group are presented as means ± SEM (n = 12). Significant differences between 2ip3N and 2ip3N + V{gamma}1 groups are indicated as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001. e and f, V{gamma}1+ cells together with {alpha}β T cells restore AHR in T cell-deficient mice. OVA-sensitized B6.TCR-β–/–{delta}–/– mice received 1 x 104 splenic V{gamma}1+ {gamma}{delta} T cells from sensitized B6.TCR-β–/– donors and 2 x 106 {alpha}β T cells from sensitized B6.TCR-{delta}–/– donors (V{gamma}1 + {alpha}β), before airway challenge. Recipients that were sensitized and challenged, but did not receive cells (2ip3N), or received only V{gamma}1+ cells (V{gamma}1) or only {alpha}β T cells ({alpha}β), are also shown. Results for each group are presented as means ± SEM (n = 4–9). Significant differences between sensitized and challenged mice, which received no cells, or V{gamma}1+ cells plus {alpha}β T cells, are indicated as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001.

 
Despite the absence of a priming requirement, it remained possible that {alpha}β T cells influence the normal development of these {gamma}{delta} T cells (26). We therefore repeated the cell-transfer experiment with V{gamma}1+ {gamma}{delta} T cells derived from B6.TCR-β–/– mice, in which they must develop in the absence of {alpha}β T cells (Fig. 1, c and d). These cells still enhanced AHR, indicating that {alpha}β T cells are not required for the development of the AHR-enhancing {gamma}{delta} T cells. However, because the cell transfer recipients (B6.TCR-{delta}–/– mice) contain {alpha}β T cells, the possibility remained that {alpha}β T cells are somehow involved in the AHR-enhancing effect of the transferred V{gamma}1+ cells. To examine this, we used OVA-sensitized mice deficient in both {alpha}β and {gamma}{delta} T cells (B6.TCR-β–/–{delta}–/–) as recipients (Fig. 1, e and f). In these mice, transferred V{gamma}1+ cells alone failed to induce AHR, but produced a small AHR response when transferred together with {alpha}β T cells, indicative of a role for {alpha}β T cells in the effector phase of the AHR response. Predictably, {alpha}β T cells transferred alone had no effect.

The comparatively weak AHR response in these mice despite a large number of transferred {alpha}β T cells (Fig. 1, e and f) suggested that most {alpha}β T cells were not effective. We reasoned that because NKT cells reportedly mediate AHR (7, 8), they might be the critical {alpha}β T cell component. To test this, we modified the original experiment of transferring V{gamma}1+ cells into sensitized B6.TCR-{delta}–/– mice by treating the recipients first with NK1.1-depleting Abs (Fig. 2, a and b) (27). Indeed, these mice no longer developed AHR following transfer of the {gamma}{delta} T cells. Because some {gamma}{delta} T cells themselves express NK1.1 (Fig. 2, c and d) (28, 29), it remained possible that residual Ab in the treated mice had inactivated the transferred {gamma}{delta} T cells. However, there was no significant difference in AHR enhancement when we compared total V{gamma}1+ cells and NK1.1-depleted V{gamma}1+ cells (Fig. 2, e and f). This result confirmed that both the transferred V{gamma}1+ {gamma}{delta} T cells and endogenous NK1.1+ cells are required to elicit AHR in the B6.TCR-{delta}–/– recipients. Although the requirement for both {alpha}β T cells and NK1.1+ cells in {gamma}{delta} T cell-induced AHR might reflect a need for one type of cellular partner, this result could also indicate that more than one additional cell type is involved, because NK1.1-expressing cells include non-T NK cells, as well as classical and nonclassical NKT cells of the {alpha}β T cell lineage (30). To test the capacity of these different cell types, we cotransferred purified preparations of each type into OVA-sensitized B6.TCR-β–/–{delta}–/– mice (Fig. 3, a and b). NK1.1+ {alpha}β T cells cotransferred with V{gamma}1+ {gamma}{delta} T cells elicited a significant AHR response, whereas neither NK1.1+ {alpha}β T cells alone, or either NK1.1– {alpha}β T cells or NK1.1+ TCR-β– NK cells cotransferred with the {gamma}{delta} T cells, enhanced AHR. This indicated that {alpha}β NKT cells (invariant or other) synergize with V{gamma}1+ {gamma}{delta} T cells to produce AHR. To distinguish between the two, we transferred purified iNKT cells based on staining with {alpha}GalCer-loaded CD1d/β2m tetramers together with V{gamma}1+ {gamma}{delta} T cells (Fig. 3, c and d). This combination elicited a strong AHR response. Notably, iNKT cells alone, or tetramer-negative {alpha}β T cells together with the {gamma}{delta} T cells, had no effect. Finally, to test whether iNKT cells are the only NK1.1+ cell population capable of synergy with the AHR-enhancing {gamma}{delta} T cells, we compared the effect of NK1.1+ {alpha}β T cells that were either tetramer positive or negative (Fig. 3, e and f). Only NK1.1+ {alpha}β T cells that were tetramer positive induced AHR when cotransferred with V{gamma}1+ {gamma}{delta} T cells, suggesting that the synergism only involves iNKT cells.


Figure 2
View larger version (21K):
[in this window]
[in a new window]

  		FIGURE 2. V{gamma}1+ {gamma}{delta} T cells fail to mediate AHR when NK1.1+ cells are absent. AHR was monitored by measuring RL (a and e) and Cdyn (b and f). a and b, V{gamma}1+ cells fail to restore AHR in {gamma}{delta} T cell-deficient mice pretreated with anti-NK1.1 mAb. OVA-sensitized B6.TCR-{delta}–/– mice were treated with mAb PK136 (200 µg i.v.), received 1 x 104 splenic V{gamma}1+ {gamma}{delta} T cells 3 days later, and were then challenged via the airways (NK1.1-depleted, 2ip3N + V{gamma}1). Recipients that were only sensitized and challenged (2ip3N) and those that were sensitized and challenged and treated with the Ab (NK1.1-depleted, 2ip3N) are also shown. Results for each group are presented as means ± SEM (n = 4). Significant differences between 2ip3N and 2ip3N, NK1.1-depleted groups are indicated as follows: *, p < 0.05. c and d, Depletion of NK1.1+ cells within the V{gamma}1+ population. C57BL/6 mice were treated with mAb PK136 (200 µg i.v.) and 3 days later, NAD splenocytes were stained for TCR-{delta}, V{gamma}1, and NK1.1. Cytofluorimetric analysis shows that ~20% of gated splenic V{gamma}1+ {gamma}{delta} T cells express NK1.1 (c) and that the treatment with mAb PK136 removes most of these cells (d). e and f, NK1.1– V{gamma}1+ {gamma}{delta} T cells enhance AHR. OVA-sensitized B6.TCR-{delta}–/– mice received 1 x 104 splenic V{gamma}1+ {gamma}{delta} T cells from C57BL/6 donors before airway challenge. The cell donors were either untreated or received mAb PK136 i.v., 3 days before cell transfer (V{gamma}1 from B6 and V{gamma}1 from NK1.1-depleted B6). Recipients that were sensitized and challenged, but did not receive cells, are also shown (no cells transferred). Results for each group are presented as means ± SEM (n = 7–8). Significant differences between mice that received no cells or V{gamma}1 cells are indicated as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001. Significant difference between mice that had received V{gamma}1+ cells from B6 vs from NK1.1-depleted B6 (f) is as follows: #, p < 0.05.

 

Figure 3
View larger version (30K):
[in this window]
[in a new window]

  		FIGURE 3. V{gamma}1+ {gamma}{delta} T cells synergize with NKT cells in mediating AHR. AHR was monitored by measuring RL (a, c, and e) and Cdyn (b, d, and f). a and b, V{gamma}1+ cells together with NK1.1+ {alpha}β T cells restore AHR in T cell-deficient mice. OVA-sensitized B6.TCR-β–/–{delta}–/– mice received 1 x 104 splenic V{gamma}1+ {gamma}{delta} T cells from sensitized B6.TCR-β–/– donors and 2 x 104 NK1.1+ {alpha}β T cells from sensitized B6.TCR-{delta}–/– donors (V{gamma}1 + NK1.1+{alpha}β), before airway challenge. Recipients that were sensitized and challenged, but did not receive cells (no cell transferred), or that received 2 x 104 NK1.1+ {alpha}β T cells (NK1.1+{alpha}β) alone, V{gamma}1+ cells plus 2 x 106 NK1.1– {alpha}β T cells (V{gamma}1 + NK1.1–{alpha}β), or V{gamma}1+ cells plus 9 x 104 NK1.1+ non-T cells (V{gamma}1 + NK), are also shown. Results for each group are presented as means ± SEM (n = 6–7). Significant differences between mice that received no cells or V{gamma}1+ cells plus NK1.1+ {alpha}β T cells are indicated as follows: **, p < 0.01; ***, p < 0.001. c and d, V{gamma}1+ cells together with CD1d tetramer+ {alpha}β T cells restore AHR in T cell-deficient mice. OVA-sensitized B6.TCR-β–/–{delta}–/– mice received 1 x 104 splenic V{gamma}1+ {gamma}{delta} T cells from sensitized B6.TCR-β–/– donors and 2 x 104 CD1d tetramer+ {alpha}β T cells from sensitized B6.TCR-{delta}–/– donors (V{gamma}1 + Tet+ {alpha}β), before airway challenge. Recipients that were sensitized and challenged, but did not receive cells (no cells), or that received 2 x 104 Tet+ {alpha}β T cells (Tet+ {alpha}β) alone, or V{gamma}1+ cells plus 2 x 104 Tet- {alpha}β T cells (V{gamma}1 + Tet– {alpha}β), are also shown. Results for each group are presented as means ± SEM (n = 4–5). Significant differences between mice that received no cells or V{gamma}1+ plus NK1.1+ {alpha}β T cells are indicated as follows: ***, p < 0.001. e and f, Only NK1.1+ {alpha}β T cells that are also CD1d tetramer+ synergize with V{gamma}1+ {gamma}{delta} T cells in mediating AHR. OVA-sensitized B6.TCR-β–/–{delta}–/– mice received 1 x 104 splenic V{gamma}1+ {gamma}{delta} T cells from sensitized B6.TCR-β–/– mice and 2 x 104 NK1.1+ CD1d tetramer+ {alpha}β T cells from sensitized B6.TCR-{delta}–/– donors (V{gamma}1 + NK1.1+Tet+ {alpha}β), before airway challenge. Recipients that were sensitized and challenged, but did not receive cells (no cell transferred), or that received V{gamma}1+ cells and 2 x 104 NK1.1+Tet– {alpha}β T cells (V{gamma}1 + NK1.1+Tet– {alpha}β), or V{gamma}1+ cells plus 2 x 104 NK1.1–Tet– {alpha}β T cells (V{gamma}1 + NK1.1–Tet– {alpha}β), are also shown. Results for each group are presented as means ± SEM (n = 5–6). Significant differences between mice that received no cells or V{gamma}1+ cells plus NK1.1+ {alpha}β T cells are indicated as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001.

 
iNKT cells have a limited TCR repertoire (18). However, V{gamma}1+ cells can express several V{delta} genes (Fig. 4a). We purified V{gamma}1+ cells expressing individual V{delta}s and examined their ability to induce AHR (Fig. 4, b and c). Only V{gamma}1+V{delta}5+ cells induced AHR, indicating that the TCR repertoire of AHR-enhancing innate {gamma}{delta} T cells is highly limited as well. Thus, as far as T cells are concerned, the combined action of two innate T cell types is sufficient to mediate AHR in the OVA model.


Figure 4
View larger version (23K):
[in this window]
[in a new window]

  		FIGURE 4. Comparison of V{gamma}1+ {gamma}{delta} T cells expressing different V{delta}s for their ability to mediate AHR. a, V{delta} expression among V{gamma}1+ {gamma}{delta} T cells in B6.TCR-β–/– spleen. NAD splenocytes of adult B6.TCR-β–/– mice were stained with Abs against V{gamma}1, TCR-{delta}, and several V{delta}s, and analyzed cytofluorimetrically. Results for each group are presented as means ± SEM (n = 5–11). b and c, Reconstitution of {gamma}{delta} T cell-deficient mice with V{delta}+ fractions of V{gamma}1+ cells. OVA-sensitized B6.TCR-{delta}–/– mice received 1 x 104 sorted V{gamma}1+ {gamma}{delta} T cells from untreated B6.TCR-β–/– spleen, expressing the indicated V{delta}s, before airway challenge (2ip3N + V{gamma}1). Recipients that were sensitized and challenged, but did not receive cells (no cell transferred), are also shown. AHR was monitored by measuring RL (b) and Cdyn (c). Results for each group are presented as means ± SEM (n = 5–8). Significant differences between mice that received no cells or V{gamma}1+ cells are indicated as follows: **, p < 0.01; ***, p < 0.001.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
There is currently some debate concerning the role of different types of lymphocytes in allergic airway disease. With regard to AHR in the OVA models, B cells were found to be required in at least one model (31), as well as in a hapten model of nonatopic asthma (32). However, neither {alpha}β T cells nor {gamma}{delta} T cells are always required for the development of AHR (10, 20), and the role of NKT cells has been controversial (11, 15, 33, 34). In studies investigating the effect of NKT cells on AHR and airway inflammation, contributions of conventional CD4+ {alpha}β T cells have been ruled out (35), but not of {gamma}{delta} T cells. Some of the current controversy therefore might be resolved by taking into account that the NKT cells can depend on {gamma}{delta} T cells to express their AHR-enhancing potential.

The present study confirms that innate lymphocyte populations, including iNKT cells, can play a role in the allergic airway disease induced by OVA. In this role, the innate lymphocytes appear to be independent of the allergen-specific T cells, but they cannot fully replace them. We have previously reported that, although {gamma}{delta} T cells can have a strong effect on AHR, they do not substantially alter airway cytokines or eosinophilic inflammation (19). This difference was maintained in the current study, because {gamma}{delta} T cells whether or not they were cotransferred with iNKT cells did not induce substantial changes in airway eosinophils compared with controls that did not receive transferred cells (Table I). However, treatment with the anti-NK1.1 mAb reduced airway eosinophilic infiltrations.

Most interestingly, our findings show that in the absence of allergen-specific T cells, neither {gamma}{delta} T cells nor iNKT cells alone can mediate AHR. iNKT cells have been previously implicated in allergic airway inflammation and AHR even in mice lacking CD4+ allergen-specific {alpha}β T cells (7, 8), but a dependence on {gamma}{delta} T cells was not noted. In contrast to these studies, and other studies with conventional T cells (36), we have transferred much smaller numbers of cells (104 V{gamma}1+ {gamma}{delta} T cells and 2 x 104 iNKT cells), which may be crucial in detecting the mutual dependence of these cell types. If quantities of cytokines (e.g., IL-13) are critical in the development of eosinophilic inflammation, the small numbers of transferred innate T cells might also explain why no effect of these cells on eosinophilic airway infiltration was seen (Table I).

We have not addressed the possible involvement of other lymphocytes remaining in the T cell-deficient recipients, including B cells, which might be capable of recognizing OVA. However, if such cells are present, they alone are incapable of mediating AHR. Neither the iNKT cells nor the {gamma}{delta} T cells appear to recognize OVA, although it is difficult to rule out this possibility entirely (37, 38). Whether they recognize other components in the OVA preparation used for sensitization and challenge (e.g., LPS), autologous ligands induced by the treatment of the recipients, or no ligands at all remains to be determined. Candidate ligands might include inducible self-lipids (39), and phospholipids in particular. We found that murine cells expressing V{gamma}1 exhibit a spontaneous cytokine response in vitro, which might be based on the recognition of self-ligands (40, 41); such cells also responded to certain anionic phospholipids (42). Interestingly, human CD1d-restricted {gamma}{delta} T cells were also stimulated by phospholipids (43), and their response to phosphatidylethanolamine could be correlated with allergic hyperresponsiveness to pollen allergen (44). The limited TCR repertoires of the innate T cells studied in this work might well be shaped entirely by developmental constraints, rather than allergen-driven peripheral selection.

Our study does not directly address the mechanism underlying the synergy between AHR-enhancing {gamma}{delta} T cells and iNKT cells. However, because of the small numbers of cells transferred, direct cell-cell interactions would appear less likely, although interactions involving cell contacts with an intermediary such as a dendritic cell (DC) might well occur. In other studies, we have colocalized V{gamma}1+ {gamma}{delta} T cells and DC in lung and spleen (45), and NKT cells are known to interact with DC as well. We have also shown previously that adoptively transferred V{gamma}1+ cells increase levels of IL-13 and IL-5 in the airways (19). Because iNKT cells can produce IL-13 (7), perhaps the {gamma}{delta} T cells stimulate their cytokine production. Having identified the functional synergy between {gamma}{delta} T cells and iNKT cells, it now seems worthwhile to define the underlying molecular mechanisms.

Cooperation between different lymphocyte types has long been recognized as a hallmark of the adaptive, Ag-specific immune response, exemplified by the classical mechanism of direct T-B cooperation, but also including synergistic interactions between Ag-specific T cells and innate lymphocyte types. Whether such interactions are direct or involve cellular intermediates such as the multifunctional DC, all appear to benefit from the different functional potentials of the participating lymphocytes. The example of a synergism between {gamma}{delta} T cells and iNKT cells described in this study probably is based as well upon a complementary functional potential of these innate lymphocytes. The observation that V{gamma}1+V{delta}6+ {gamma}{delta} T cells are not AHR enhancing is consistent with this notion. This subset of the V{gamma}1+ population contains {gamma}{delta} T cells with NKT-like properties (29) and thus would not be expected to complement the iNKT cells.

Our findings may represent a specific case of the synergism between {gamma}{delta} and {alpha}β T cells, which has been proposed some time ago (23). In addition, because not only iNKT cells (7), but also the AHR-enhancing {gamma}{delta} T cells (this study) could be derived from unprimed donors and express a very limited TCR repertoire, our study suggests that lymphocytic synergism might be a mechanism used not only by adaptive, but also by innate T-dependent immune responses.


   Acknowledgments
 
We thank Drs. Philippa Marrack, Max Cooper, David Talmage, and Katsuyuki Takeda for advice and support, and Joshua Loomis, Shirley Sobus, and William Townend for expert help with cell sorting. Biotinylated mouse CD1d monomers were generously provided by the National Institutes of Health tetramer core facility.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by National Institutes of Health Grants HL65410 and AI40611 (to W.K.B.), AI44920 and AI063400 (to R.L.O.), HL36577 and HL61005 (to E.W.G.), and AI057485 (to L.G.), and by Environmental Protection Agency Grant R825702 (to E.W.G.). Support was also provided by a postdoctoral fellowship from the American Cancer Society (to J.L.M.). Back

2 Address correspondence and reprint requests to Dr. Willi K. Born, Integrated Department of Immunology, National Jewish Medical and Research Center, 1400 Jackson Street, GB K409, Denver, CO 80206. E-mail address: bornw{at}njc.org Back

3 Abbreviations used in this paper: iNKT, invariant NKT; {alpha}GalCer, {alpha}-galactosylceramide; AHR, airway hyperresponsiveness; β2m, β2-microglobulin; BAL, bronchoalveolar lavage; Cdyn, dynamic compliance; DC, dendritic cell; MCh, methacholine; NAD, nonadherent; RL, lung resistance. Back

Received for publication June 5, 2007. Accepted for publication June 28, 2007.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Claman, H. N., E. A. Chaperon, R. F. Triplett. 1966. Immunocompetence of transferred thymus-marrow cell combinations. J. Immunol. 97: 828-832. [Abstract/Free Full Text]
  2. Castellino, F., A. Y. Huang, G. Altan-Bonnet, S. Stoll, C. Scheinecker, R. N. Germain. 2006. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440: 890-895. [Medline]
  3. Munz, C., R. M. Steinman, S. Fujii. 2005. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J. Exp. Med. 202: 203-207. [Abstract/Free Full Text]
  4. Wills-Karp, M.. 1999. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17: 255-281. [Medline]
  5. Robinson, D. S., O. Hamid, S. Ying, A. Tsicopoulos, J. Barkans, A. M. Bentley, C. Corrigan, S. R. Durham, A. B. Kay. 1992. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 326: 298-304. [Abstract]
  6. Hamelmann, E., A. Oshiba, J. Paluh, K. Bradley, J. Loader, T. A. Potter, G. L. Larsen, E. W. Gelfand. 1996. Requirement for CD8+ T cells in the development of airway hyperresponsiveness in a murine model of airway sensitization. J. Exp. Med. 183: 1719-1729. [Abstract/Free Full Text]
  7. Akbari, O., P. Stock, E. Meyer, M. Kronenberg, S. Sidobre, T. Nakayama, M. Taniguchi, M. J. Grusby, R. H. DeKruyff, D. T. Umetsu. 2003. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9: 582-588. [Medline]
  8. Lisbonne, M., S. Diem, A. de Castro Keller, J. Lefort, L. M. Araujo, P. Hachem, J. M. Fourneau, S. Sidobre, M. Kronenberg, M. Taniguchi, et al 2003. Cutting edge: invariant V{alpha}14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J. Immunol. 171: 1637-1641. [Abstract/Free Full Text]
  9. Zuany-Amorim, C., C. Ruffie, S. Haile, B. B. Vargaftig, P. Pereira, M. Pretolani. 1998. Requirement for {gamma}{delta} T cells in allergic airway inflammation. Science 280: 1265-1267. [Abstract/Free Full Text]
  10. Lahn, M., A. Kanehiro, K. Takeda, A. Joetham, J. Schwarze, G. Koehler, R. O’Brien, E. W. Gelfand, W. Born. 1999. Negative regulation of airway responsiveness that is dependent on {gamma}{delta} T cells and independent of {alpha}β T cells. Nat. Med. 5: 1150-1156. [Medline]
  11. Das, Y., P. Eynott, R. Jupp, A. Bothwell, L. Van Kaer, Y. Shi, G. Das. 2006. Natural killer T cells and CD8+ T cells are dispensable for T cell-dependent allergic airway inflammation. Nat. Med. 12: 1345-1347. [Medline]
  12. Bendelac, A., P. B. Savage, L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336. [Medline]
  13. Kinjo, Y., M. Kronenberg. 2005. V{alpha}14i NKT cells are innate lymphocytes that participate in the immune response to diverse microbes. J. Clin. Immunol. 25: 522-533. [Medline]
  14. Yu, K. O., S. A. Porcelli. 2005. The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy. Immunol. Lett. 100: 42-55. [Medline]
  15. Akbari, O., J. L. Faul, E. G. Hoyte, G. J. Berry, J. Wahlstrom, M. Kronenberg, R. H. DeKruyff, D. T. Umetsu. 2006. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N. Engl. J. Med. 354: 1117-1129. [Abstract/Free Full Text]
  16. Bendelac, A., M. N. Rivera, S.-H. Park, J. H. Roark. 1997. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 15: 535-562. [Medline]
  17. Matsuda, J. L., O. V. Naidenko, L. Gapin, T. Nakayama, M. Taniguchi, C. R. Wang, Y. Koezuka, M. Kronenberg. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192: 741-754. [Abstract/Free Full Text]
  18. Matsuda, J. L., L. Gapin. 2005. Developmental program of mouse V{alpha}14i NKT cells. Curr. Opin. Immunol. 17: 122-130. [Medline]
  19. Hahn, Y.-S., C. Taube, N. Jin, L. Sharp, J. M. Wands, M. Kemal Aydintug, M. Lahn, S. A. Huber, R. L. O’Brien, E. W. Gelfand, W. K. Born. 2004. Different potentials of {gamma}{delta} T cell subsets in regulating airway responsiveness: V{gamma}1+ cells, but not V{gamma}4+ cells, promote airway hyperreactivity, TH2 cytokines, and airway inflammation. J. Immunol. 172: 2894-2902. [Abstract/Free Full Text]
  20. Lahn, M., A. Kanehiro, K. Takeda, J. Terry, Y.-S. Hahn, M. K. Aydintug, A. Konowal, K. Ikuta, R. L. O’Brien, E. W. Gelfand, W. K. Born. 2002. MHC class I-dependent V{gamma}4+ pulmonary T cells regulate {alpha}β T cell-independent airway responsiveness. Proc. Natl. Acad. Sci. USA 99: 8850-8855. [Abstract/Free Full Text]
  21. Hahn, Y.-S., C. Taube, N. Jin, K. Takeda, J.-W. Park, J. M. Wands, M. K. Aydintug, C. L. Roark, M. Lahn, R. L. O’Brien, et al 2003. V{gamma}4+ T cells regulate airway hyperreactivity to methacholine in ovalbumin-sensitized and challenged mice. J. Immunol. 171: 3170-3178. [Abstract/Free Full Text]
  22. Jin, N., C. Taube, L. Sharp, Y.-S. Hahn, X. Yin, J. M. Wands, C. L. Roark, R. L. O’Brien, E. W. Gelfand, W. K. Born. 2005. Mismatched antigen prepares {gamma}{delta} T cells for suppression of airway hyperresponsiveness. J. Immunol. 174: 2671-2679. [Abstract/Free Full Text]
  23. Kasahara, Y., C. H. Chen, M. D. Cooper. 1993. Growth requirements for avian {gamma}{delta} T cells include exogenous cytokines, receptor ligation and in vivo priming. Eur. J. Immunol. 23: 2230-2236. [Medline]
  24. Pereira, P., D. Gerber, S. Y. Huang, S. Tonegawa. 1995. Ontogenic development and tissue distribution of V{gamma}1-expressing {gamma}/{delta} T lymphocytes in normal mice. J. Exp. Med. 182: 1921-1930. [Abstract/Free Full Text]
  25. Heilig, J. S., S. Tonegawa. 1986. Diversity of murine {gamma} genes and expression in fetal and adult T lymphocytes. Nature 322: 836-840. [Medline]
  26. Silva-Santos, B., D. J. Pennington, A. C. Hayday. 2005. Lymphotoxin-mediated regulation of {gamma}{delta} cell differentiation by {alpha}β T cell progenitors. Science 307: 925-928. [Abstract/Free Full Text]
  27. Sentman, C. L., J. Hackett, Jr, T. A. Morre, M. M. Tutt, M. Bennett, V. Kumar. 1989. Pan natural killer cell monoclonal antibodies and their relationship to the NK1.1 antigen. Hybridoma 8: 605-614. [Medline]
  28. Vicari, A. P., S. Mocci, P. Openshaw, A. O’Garra, A. Zlotnik. 1996. Mouse {gamma}{delta} TCR+NK1.1+ thymocytes specifically produce interleukin-4, are major histocompatibility complex class I independent, and are developmentally related to Ab TCR+NK1.1+ thymocytes. Eur. J. Immunol. 26: 1424-1429. [Medline]
  29. Azuara, V., J. P. Levraud, M. P. Lembezat, P. Pereira. 1997. A novel subset of adult {gamma}{delta} thymocytes that secretes a distinct pattern of cytokines and expresses a very restricted T cell receptor repertoire. Eur. J. Immunol. 27: 544-553. [Medline]
  30. Godfrey, D. I., H. R. MacDonald, M. Kronenberg, M. J. Smyth, L. Van Kaer. 2004. NKT cells: what’s in a name?. Nat. Rev. Immunol. 4: 231-237. [Medline]
  31. Hamelmann, E., A. T. Vella, A. Oshiba, J. W. Kappler, P. Marrack, E. W. Gelfand. 1997. Allergic airway sensitization induces T cell activation but not airway hyperresponsiveness in B cell-deficient mice. Proc. Natl. Acad. Sci. USA 94: 1350-1355. [Abstract/Free Full Text]
  32. Kawikova, I., V. Palival, M. Szczepanik, A. Itakura, M. Fukui, R. A. Campos, G. P. Geba, R. J. Homer, B. P. Iliopoulou, J. S. Pober, et al 2004. Airway hyper-reactivity mediated by B-1 cell immunoglobulin M antibody generating complement C5a at 1 day post-immunization in a murine hapten model of non-atopic asthma. Immunology 113: 234-245. [Medline]
  33. Vijayanand, P., G. Seumois, C. Pickard, R. M. Powell, G. Angco, D. Sammut, S. D. Gadola, P. S. Friedman, R. Djukanovic. 2007. Invariant natural killer T cells and chronic obstructive pulmonary disease. N. Engl. J. Med. 356: 1410-1422. [Abstract/Free Full Text]
  34. Matsuda, H., T. Suda, E. Sato, T. Nagata, Y. Koide, K. Chida, H. Nakamura. 2005. {alpha}-Galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation. Am. J. Respir. Cell Mol. Biol. 33: 22-31. [Abstract/Free Full Text]
  35. Meyer, E. H., S. Goya, O. Akbari, G. J. Berry, P. B. Savage, M. Kronenberg, T. Nakayama, R. H. DeKruyff, D. T. Umetsu. 2006. Glycolipid activation of invariant T cell receptor+ NKT cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells. Proc. Natl. Acad. Sci. USA 103: 2782-2787. [Abstract/Free Full Text]
  36. Miyahara, N., B. J. Swanson, K. Takeda, C. Taube, S. Miyahara, T. Kodama, A. Dakhama, V. L. Ott, E. W. Gelfand. 2004. Effector CD8+ T cells mediate inflammation and airway hyper-responsiveness. Nat. Med. 10: 865-869. [Medline]
  37. McMenamin, C., C. Pimm, M. McKersey, P. G. Holt. 1994. Regulation of IgE responses to inhaled antigen in mice by antigen-specific {gamma}{delta} T cells. Science 265: 1869-1871. [Abstract/Free Full Text]
  38. Tangri, S., L. Brossay, N. Burdin, D. J. Lee, M. Corr, M. Kronenberg. 1998. Presentation of peptide antigens by mouse CD1 requires endosomal localization and protein antigen processing. Proc. Natl. Acad. Sci. USA 95: 14314-14319. [Abstract/Free Full Text]
  39. De Libero, G., A. P. Moran, H.-J. Gober, E. Rossy, A. Shamshiev, O. Chelnokova, Z. Mazorra, S. Vendetti, A. Sacchi, M. M. Prendergast, et al 2005. Bacterial infections promote T cell recognition of self-glycolipids. Immunity 22: 763-772. [Medline]
  40. O’Brien, R. L., M. P. Happ, A. Dallas, E. Palmer, R. Kubo, W. K. Born. 1989. Stimulation of a major subset of lymphocytes expressing T cell receptor {gamma}{delta} by an antigen derived from Mycobacterium tuberculosis. Cell 57: 667-674. [Medline]
  41. O’Brien, R. L., Y.-X. Fu, R. Cranfill, A. Dallas, C. Reardon, J. Lang, S. R. Carding, R. Kubo, W. Born. 1992. Heat shock protein Hsp-60 reactive {gamma}{delta} cells: a large, diversified T lymphocyte subset with highly focused specificity. Proc. Natl. Acad. Sci. USA 89: 4348-4352. [Abstract/Free Full Text]
  42. Born, W. K., M. Vollmer, C. Reardon, E. Matsuura, D. R. Voelker, P. C. Giclas, R. L. O’Brien. 2003. Hybridomas expressing {gamma}{delta} T-cell receptors respond to cardiolipin and β2-glycoprotein 1 (apolipoprotein H). Scand. J. Immunol. 58: 374-381. [Medline]
  43. Agea, E., A. Russano, O. Bistoni, R. Mannucci, I. Nicoletti, L. Corazzi, A. D. Postle, G. De Libero, S. A. Porcelli, F. Spinozzi. 2005. Human CD1-restricted T cell recognition of lipids from pollens. J. Exp. Med. 202: 295-308. [Abstract/Free Full Text]
  44. Russano, A. M., E. Agea, L. Corazzi, A. D. Postle, G. De Libero, S. A. Porcelli, F. De Benedictis, F. Spinozzi. 2006. Recognition of pollen-derived phosphatidyl-ethanolamine by human CD1d-restricted {gamma}{delta} T cells. J. Allergy Clin. Immunol. 117: 1178-1184. [Medline]
  45. O’Brien, R. L., C. L. Roark, N. Jin, M. K. Aydintug, J. D. French, J. L. Chain, J. M. Wands, M. Johnston, W. K. Born. 2007. {gamma}{delta} T cell receptors: functional correlations. Immunol. Rev. 215: 77-88. [Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
Y. Huang, N. Jin, C. L. Roark, M. K. Aydintug, J. M. Wands, H. Huang, R. L. O'Brien, and W. K. Born
The Influence of IgE-Enhancing and IgE-Suppressive {gamma}{delta} T Cells Changes with Exposure to Inhaled Ovalbumin
J. Immunol., July 15, 2009; 183(2): 849 - 855.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
S. Matsubara, K. Takeda, N. Jin, M. Okamoto, H. Matsuda, Y. Shiraishi, J. W. Park, G. McConville, A. Joetham, R. L. O'Brien, et al.
V{gamma}1+ T Cells and Tumor Necrosis Factor-Alpha in Ozone-Induced Airway Hyperresponsiveness
Am. J. Respir. Cell Mol. Biol., April 1, 2009; 40(4): 454 - 463.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Jin, C. L. Roark, N. Miyahara, C. Taube, M. K. Aydintug, J. M. Wands, Y. Huang, Y.-S. Hahn, E. W. Gelfand, R. L. O'Brien, et al.
Allergic Airway Hyperresponsiveness-Enhancing {gamma}{delta} T Cells Develop in Normal Untreated Mice and Fail to Produce IL-4/13, Unlike Th2 and NKT Cells
J. Immunol., February 15, 2009; 182(4): 2002 - 2010.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Cook, N. Miyahara, N. Jin, J. M. Wands, C. Taube, C. L. Roark, T. A. Potter, E. W. Gelfand, R. L. O'Brien, and W. K. Born
Evidence That CD8+ Dendritic Cells Enable the Development of {gamma}{delta} T Cells That Modulate Airway Hyperresponsiveness
J. Immunol., July 1, 2008; 181(1): 309 - 319.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
O. Akbari, P. Stock, E. H. Meyer, G. J. Freeman, A. H. Sharpe, D. T. Umetsu, and R. H. DeKruyff
ICOS/ICOSL Interaction Is Required for CD4+ Invariant NKT Cell Function and Homeostatic Survival
J. Immunol., April 15, 2008; 180(8): 5448 - 5456.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jin, N.
Right arrow Articles by Born, W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jin, N.
Right arrow Articles by Born, W. K.
Right arrowPubmed/NCBI databases
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS